Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Times Interest Earned (2016 - 2025)

Historic Times Interest Earned for Theravance Biopharma (TBPH) over the last 10 years, with Q3 2025 value amounting to -$11.27.

  • Theravance Biopharma's Times Interest Earned rose 3451.03% to -$11.27 in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.01, marking a year-over-year increase of 2528.58%. This contributed to the annual value of -$18.44 for FY2024, which is 2266.49% up from last year.
  • Latest data reveals that Theravance Biopharma reported Times Interest Earned of -$11.27 as of Q3 2025, which was up 3451.03% from -$4.11 recorded in Q2 2025.
  • Theravance Biopharma's 5-year Times Interest Earned high stood at -$4.11 for Q2 2025, and its period low was -$45.29 during Q1 2023.
  • For the 5-year period, Theravance Biopharma's Times Interest Earned averaged around -$17.99, with its median value being -$17.2 (2024).
  • Per our database at Business Quant, Theravance Biopharma's Times Interest Earned tumbled by 93697.73% in 2021 and then surged by 8314.61% in 2025.
  • Theravance Biopharma's Times Interest Earned (Quarter) stood at -$26.28 in 2021, then dropped by 20.59% to -$31.69 in 2022, then surged by 68.4% to -$10.02 in 2023, then crashed by 42.85% to -$14.31 in 2024, then rose by 21.27% to -$11.27 in 2025.
  • Its Times Interest Earned was -$11.27 in Q3 2025, compared to -$4.11 in Q2 2025 and -$22.45 in Q1 2025.